Executive summary: Unrecognized STIs, specifically genital mycoplasma bacteria like Mycoplasma genitalium and Ureaplasma species, routinely cause recurrent genitourinary conditions such as pelvic inflammatory disease, recurrent bacterial vaginitis, and chronic urinary tract infections. Physicians should use molecular testing to diagnose these pathogens and treat patients and their sexual partners with targeted antibiotics like doxycycline.Â
You see it often in your clinic. A patient returns for the third time with burning urination, or perhaps another bout of bacterial vaginitis. You prescribe standard treatments, but the symptoms always come back. These frustrating cycles leave your patients exhausted and searching for answers. What if the root cause is an infection you’re not routinely testing for?
Genital mycoplasma bacteria represent a significant, yet frequently overlooked, source of patient morbidity. Even though the Centers for Disease Control and Prevention officially classified Mycoplasma genitalium as a sexually transmitted infection in 2015, many healthcare providers remain unaware of its impact. By recognizing unrecognized STIs, you can solve these clinical mysteries and dramatically improve your patients’ quality of life.
Addressing these hidden infections requires a comprehensive understanding of how they behave, how they present, and how to target them effectively. Let’s explore how you can identify and treat these stealthy pathogens in your daily practice.
Related CE course for physicians: Genital Mycoplasma Infections: Unrecognized STIs
What are the specific genital mycoplasma bacteria?
Genital mycoplasma bacteria belong to the Mollicutes class and the Mycoplasmataceae family. When we talk about these unrecognized STIs in a clinical setting, we focus primarily on four distinct species:
- Mycoplasma genitalium (Mgen)Â
- Mycoplasma hominis (MH)Â
- Ureaplasma urealyticum (UU)Â
- Ureaplasma parvum (UP)Â
These organisms hold a unique structural characteristic: they are the smallest free-living bacteria and they entirely lack a cell wall. Instead of a cell wall, they utilize a three-layered cellular membrane. This specific structural difference prevents them from showing up on a standard Gram stain. It also renders them completely resistant to common antibiotics that target cell wall synthesis, such as penicillins and cephalosporins.
While the CDC explicitly labels Mgen as an STI, the other three species also transmit through sexual contact and cause considerable urogenital harm. Women generally experience higher rates of colonization than men. By acknowledging all four species as potential pathogens, you empower yourself to treat chronic genitourinary symptoms that traditional testing panels miss.
How do genital mycoplasma bacteria evade standard immune detection?
Genital mycoplasma bacteria possess several biological advantages that help them hide from the human immune system. Because they lack limited biosynthesis capabilities, they survive by invading the host’s epithelial cells. Invading the host’s cells allows genital mycoplasma bacteria to escape detection by circulating immune responses.
These pathogens also grow exceptionally slowly. They form specialized biofilms that shield them from both the immune system and pharmacological interventions. Mycoplasma hominis, for example, can alter its cell membrane surface and switch its carbon metabolism when stressed, effectively slowing its growth rate to resist antibiotics.
Choose molecular testing over standard bacterial cultures if you want timely, accurate results. Because Mycoplasma genitalium grows so slowly, a standard culture can take up to six months to yield a positive result. This delay makes conventional culturing clinically useless for patients suffering from unrecognized STIs.
What clinical signs point to an unrecognized STI?
Patients infected with genital mycoplasma bacteria often present with symptoms that mimic other common conditions. You should suspect unrecognized STIs when your patients complain of persistent, recurrent genitourinary discomfort that fails to resolve with standard first-line therapies.
In women, Ureaplasma species produce ammonia, which raises vaginal pH and perfectly mimics bacterial vaginitis. Research shows that women colonized by Ureaplasma species face four times the risk of developing bacterial vaginitis. You should also test for unrecognized STIs in women presenting with sterile pyuria, chronic overactive bladder, post-coital bleeding, or recurrent pelvic inflammatory disease. In fact, Mycoplasma genitalium drives a 67% increase in the odds of pelvic inflammatory disease.
In men, these unrecognized STIs most frequently present as non-gonococcal urethritis. If left untreated, the infection can easily progress to epididymitis or orchitis. Interestingly, the physical exams for these infections often appear remarkably subtle. A man with orchitis caused by Mycoplasma genitalium might experience severe testicular pain but display no fever, lymphadenopathy, or prominent swelling.
How do unrecognized STIs impact pregnancy and fertility?
The damage caused by genital mycoplasma bacteria extends far beyond simple discomfort. These unrecognized STIs severely impact reproductive health for both men and women. Studies demonstrate that Mycoplasma genitalium, Mycoplasma hominis, and Ureaplasma urealyticum all significantly increase the odds of male and female infertility.
During pregnancy, these pathogens pose severe risks to both the mother and the developing fetus. Genital mycoplasma bacteria routinely trigger preterm labor, premature rupture of membranes, and chorioamnionitis. Furthermore, up to 60% of post-abortal pelvic inflammatory disease cases link directly back to Mycoplasma genitalium.
Neonates born to infected mothers can acquire the bacteria during delivery. This transmission leads to serious neonatal complications, including pneumonia, bacteremia, and respiratory distress syndrome. By proactively identifying and treating these unrecognized STIs in your symptomatic patients of reproductive age, you can prevent these devastating long-term reproductive complications.
How should physicians test for genital mycoplasma bacteria?
Accurate diagnosis relies heavily on choosing the right testing modality. As mentioned, cultures fail to provide timely answers. Therefore, physicians must utilize nucleic acid amplification tests (NAATs) to accurately identify genital mycoplasma bacteria.
For female patients, you can collect samples via vaginal or endocervical swabs. Women can also reliably collect their own vaginal swabs using Aptima collection tubes. For male patients, collect first-catch urine samples or perform a urethral swab. Always test the specific anatomical site of the symptoms. For instance, men who have sex with men presenting with proctitis require an anorectal swab to capture the pathogen effectively.
Choose a macrolide-resistance assay if you diagnose a patient with Mycoplasma genitalium. Identifying macrolide resistance up front allows you to tailor your antibiotic regimen immediately, leading to first-line cure rates exceeding 90%.
What are the recommended treatments for genital mycoplasmas?
Treating unrecognized STIs requires specific antibiotic regimens, as these bacteria do not respond to beta-lactams. Doxycycline serves as the foundational first-line treatment for all genital mycoplasma bacteria.
For Ureaplasma species and Mycoplasma hominis, a standard 7-day course of doxycycline usually resolves urethritis, cervicitis, or bacterial vaginitis. Extend this treatment to 14 days if the patient has pelvic inflammatory disease.
Mycoplasma genitalium requires a more aggressive, two-step approach due to high resistance rates. The CDC recommends starting with doxycycline for seven days to lower the bacterial load. Follow this immediately with moxifloxacin for seven day. Choose a sequential regimen of doxycycline followed by azithromycin if you confirm the strain is macrolide-sensitive.
Crucially, you must treat your patient’s sexual partners concurrently. Reinfection remains the leading cause of treatment failure. Educate your patients to abstain from sexual contact until both they and their partners complete their antibiotics and their symptoms fully resolve.
Transform your patient outcomes today
By learning to spot unrecognized STIs, you hold the power to end cycles of chronic pain and frustration for your patients. Genital mycoplasma bacteria are prevalent, communicable, and highly morbid, but they are also entirely treatable.
Start considering molecular testing for Mycoplasma genitalium and Ureaplasma species the next time a patient presents with recurrent urinary tract infections, persistent bacterial vaginitis, or unexplained pelvic pain. Your clinical vigilance will protect their reproductive health, prevent neonatal complications, and ultimately restore their well-being.
Frequently asked questions about unrecognized STIs
What are the main risks of leaving genital mycoplasma bacteria untreated?
Untreated genital mycoplasma bacteria cause severe reproductive and urogenital complications. In women, they lead to pelvic inflammatory disease, chronic pelvic pain, and pregnancy complications like preterm labor. In men, they cause chronic urethritis and orchitis. Both sexes face a significantly higher risk of permanent infertility.
How long does it take to cure an unrecognized STI?
The timeline depends on the specific pathogen and clinical presentation. Simple cervicitis or urethritis caused by Ureaplasma species resolves with a 7-day course of doxycycline. Complex infections like Mycoplasma genitalium require a sequential 14-day antibiotic regimen. Symptoms typically improve within a few days of starting the appropriate targeted therapy.
What are the alternative treatments if a patient cannot take doxycycline?
If a patient has a contraindication to doxycycline, such as a severe allergy or pregnancy, alternative options exist. Physicians can use pristinamycin for Mycoplasma genitalium, azithromycin for Ureaplasma species, and clindamycin for Mycoplasma hominis. Always consult the STD Clinical Consultation Network before treating pregnant patients for these infections.
Who should be tested for genital mycoplasma bacteria?
Physicians should test symptomatic patients who present with recurrent non-gonococcal urethritis, persistent cervicitis, chronic bacterial vaginitis, or pelvic inflammatory disease that does not respond to initial therapies. Routine screening for asymptomatic individuals is not currently recommended by the CDC due to the risk of promoting antibiotic resistance.
